199 related articles for article (PubMed ID: 28026073)
1. Use of the UKHCDO Database for a postmarketing surveillance study of different doses of recombinant factor VIIa in haemophilia.
Hay CRM; Sharpe T; Dolan G;
Haemophilia; 2017 May; 23(3):376-382. PubMed ID: 28026073
[TBL] [Abstract][Full Text] [Related]
2. Exposure and safety of higher doses of recombinant factor VIIa ≥250 μg kg(-1) in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004-2008).
Neufeld EJ; Kessler CM; Gill JC; Wilke CT; Cooper DL;
Haemophilia; 2011 Jul; 17(4):650-6. PubMed ID: 21299750
[TBL] [Abstract][Full Text] [Related]
3. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registries.
Shapiro AD; Neufeld EJ; Blanchette V; Salaj P; Gut RZ; Cooper DL
Haemophilia; 2014 Jan; 20(1):e23-31. PubMed ID: 24354484
[TBL] [Abstract][Full Text] [Related]
4. Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: the experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008).
Young G; Cooper DL; Gut RZ;
Haemophilia; 2012 Nov; 18(6):990-6. PubMed ID: 22631073
[TBL] [Abstract][Full Text] [Related]
5. Treatment of acute bleeding in acquired haemophilia A with recombinant activated factor VII: analysis of 10-year Japanese postmarketing surveillance data.
Amano K; Seita I; Higasa S; Sawada A; Kuwahara M; Shima M
Haemophilia; 2017 Jan; 23(1):50-58. PubMed ID: 27457022
[TBL] [Abstract][Full Text] [Related]
6. Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders.
Birschmann I; Klamroth R; Eichler H; Schenk J; Kirchmaier CM; Halimeh S
Haemophilia; 2013 Sep; 19(5):679-85. PubMed ID: 23647644
[TBL] [Abstract][Full Text] [Related]
7. US experience with recombinant factor VIIa for surgery and other invasive procedures in acquired haemophilia: analysis from the Hemostasis and Thrombosis Research Society Registry.
Ma AD; Kessler CM; Al-Mondhiry HA; Gut RZ; Cooper DL
Haemophilia; 2016 Jan; 22(1):e18-24. PubMed ID: 26551409
[TBL] [Abstract][Full Text] [Related]
8. Evaluating and monitoring the efficacy of recombinant activated factor VIIa in patients with haemophilia and inhibitors.
Qi X; Zhao Y; Li K; Fan L; Hua B
Blood Coagul Fibrinolysis; 2014 Oct; 25(7):754-60. PubMed ID: 24806320
[TBL] [Abstract][Full Text] [Related]
9. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
Parameswaran R; Shapiro AD; Gill JC; Kessler CM;
Haemophilia; 2005 Mar; 11(2):100-6. PubMed ID: 15810910
[TBL] [Abstract][Full Text] [Related]
10. Safety and effectiveness of room temperature stable recombinant factor VIIa in patients with haemophilia A or B and inhibitors: Results of a multinational, prospective, observational study.
Kavakli K; Demartis F; Karimi M; Eshghi P; Neme D; Chambost H; Sommer L; Zak M; Benson G
Haemophilia; 2017 Jul; 23(4):575-582. PubMed ID: 28440004
[TBL] [Abstract][Full Text] [Related]
11. Assessment of individual dose utilization vs. physician prescribing recommendations for recombinant activated factor VII (rFVIIa) in paediatric and adult patients with congenital haemophilia and alloantibody inhibitors (CHwI): the Dosing Observational Study in Hemophilia (DOSE).
Gruppo RA; Kessler CM; Neufeld EJ; Cooper DL
Haemophilia; 2013 Jul; 19(4):524-32. PubMed ID: 23551918
[TBL] [Abstract][Full Text] [Related]
12. Real-world outcomes with recombinant factor VIIa treatment of acute bleeds in haemophilia patients with inhibitors: results from the international ONE registry.
Chambost H; Santagostino E; Laffan M; Kavakli K;
Haemophilia; 2013 Jul; 19(4):571-7. PubMed ID: 23557542
[TBL] [Abstract][Full Text] [Related]
13. Single-dose (270 microg kg(-1)) recombinant activated factor VII for the treatment and prevention of bleeds in haemophilia A patients with inhibitors: experience from seven European haemophilia centres.
Pan-Petesch B; Laguna P; Mital A; Stanley J; Torchet MF; Salek SZ; Salaj P
Haemophilia; 2009 May; 15(3):760-5. PubMed ID: 19298382
[TBL] [Abstract][Full Text] [Related]
14. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors.
Abshire T; Kenet G
Haemophilia; 2008 Sep; 14(5):898-902. PubMed ID: 18684126
[TBL] [Abstract][Full Text] [Related]
15. Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia.
Tiede A; Worster A
Ann Hematol; 2018 Oct; 97(10):1889-1901. PubMed ID: 29804265
[TBL] [Abstract][Full Text] [Related]
16. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison.
Young G; Shafer FE; Rojas P; Seremetis S
Haemophilia; 2008 Mar; 14(2):287-94. PubMed ID: 18081834
[TBL] [Abstract][Full Text] [Related]
17. Recombinant activated factor VII safety and efficacy in the treatment of cranial haemorrhage in patients with congenital haemophilia with inhibitors: an analysis of the Hemophilia and Thrombosis Research Society Registry (2004-2008).
Nakar C; Cooper DL; DiMichele D
Haemophilia; 2010 Jul; 16(4):625-31. PubMed ID: 20158526
[TBL] [Abstract][Full Text] [Related]
18. Patient/caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE).
Young G; Shapiro AD; Walsh CE; Gruppo RA; Gut RZ; Cooper DL
Haemophilia; 2012 May; 18(3):392-9. PubMed ID: 22171621
[TBL] [Abstract][Full Text] [Related]
19. Surgical experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX.
Valentino LA; Cooper DL; Goldstein B
Haemophilia; 2011 Jul; 17(4):579-89. PubMed ID: 21294815
[TBL] [Abstract][Full Text] [Related]
20. Ten-year experience of recombinant activated factor VII use in surgical patients with congenital haemophilia with inhibitors or acquired haemophilia in Japan.
Takedani H; Shima M; Horikoshi Y; Koyama T; Fukutake K; Kuwahara M; Ishiguro N
Haemophilia; 2015 May; 21(3):374-379. PubMed ID: 25521821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
